Tirzepatide Constipation: Causes, FDA-Label Rates & Evidence-Based Relief Protocol

Constipation is one of the four most-common GI side effects on tirzepatide — the active ingredient in both Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The Zepbound FDA label Section 6.1 reports constipation in approximately 11% of patients on the 15 mg dose vs. 5% on placebo in the SURMOUNT-1 obesity trial^[2][3]. The mechanism stacks two slow-down signals: GLP-1 receptor activation plus glucose-dependent insulinotropic polypeptide (GIP) receptor activation, both of which delay gastric emptying and slow lower-GI transit^[8][9]. This guide covers what SURMOUNT-1, SURMOUNT-4, and SURMOUNT-OSA actually reported, how tirzepatide compares head-to-head with semaglutide, the evidence-based relief protocol, and the FDA-label red flags that mean stop self-managing and call your prescriber.

The honest short answer

Tirzepatide-related constipation is real, dose-dependent, and almost always manageable without stopping the drug. The Zepbound FDA label Section 6.1 lists constipation at 11% on the 15 mg dose vs. 5% on placebo across the SURMOUNT-1 obesity program; the Mounjaro label reports a lower rate of approximately 6–7% at the 15 mg type-2-diabetes dose, since the SURPASS T2D trials enrolled a different population with shorter follow-up^[1][2][3]. Most patients respond to first-line conservative measures: deliberate fiber, adequate fluids, daily movement, and (if needed) a 200–400 mg magnesium citrate at bedtime. Stop self-managing and call your prescriber if you go 5+ days without a bowel movement, if you have progressive abdominal distension, or if vomiting joins the picture.

What SURMOUNT-1, SURMOUNT-4, and SURMOUNT-OSA actually measured

The Zepbound FDA-label constipation rates come from the SURMOUNT obesity-trial program. Jastreboff and colleagues’ SURMOUNT-1 publication in the New England Journal of Medicine (2022) is the 72-week pivotal trial in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) plus a weight-related comorbidity^[3]. In the Section 6 adverse-reactions table of the primary publication and the Zepbound FDA label that derives from it, constipation was reported in approximately 11.7% of the 15 mg arm, 11.1% of the 10 mg arm, 6.7% of the 5 mg arm, and 5.4% of placebo over 72 weeks of treatment^[2][3].

SURMOUNT-4 (Aronne 2024 JAMA) tested the maintenance question: what happens to GI tolerability if a patient stops vs. continues tirzepatide after the first ~9 months? Patients who completed a 36-week open-label tirzepatide lead-in were randomized to continue the maintenance dose (10 or 15 mg) or switch to placebo for an additional 52 weeks^[4]. Constipation rates in the continued-tirzepatide arm remained in the high single-digit-percent range over the maintenance year, vs. lower rates in the placebo-switch arm — consistent with the motility effect being present as long as the drug is on board.

SURMOUNT-OSA (Malhotra 2024 NEJM) extended the adverse-event picture into a different population: adults with moderate-to-severe obstructive sleep apnea and obesity, treated for 52 weeks with tirzepatide titrated to a maximum tolerated dose of 10 or 15 mg^[5]. Constipation appeared in the publication’s adverse-event table at single-digit-percent rates similar to SURMOUNT-1, confirming the rate is not an artifact of any one SURMOUNT population.

Mechanism — why tirzepatide’s dual agonism slows transit

Tirzepatide is a once-weekly synthetic peptide that activates two incretin receptors: the GLP-1 receptor (the same target as semaglutide, dulaglutide, and liraglutide) and the GIP receptor. Both receptors are expressed on enteric neurons, gastric smooth muscle, and the central appetite circuitry that controls hunger and satiety. Activation of either receptor slows gastric emptying; activation of both stacks the effect.

Urva and colleagues’ 2020 phase-1 PK study in Diabetes, Obesity and Metabolism measured tirzepatide’s gastric-emptying effect directly using acetaminophen-absorption pharmacokinetics^[8]. The headline finding: tirzepatide produced a transient, dose-dependent delay in gastric emptying that on the first dose was comparable in magnitude to long-acting GLP-1 receptor agonists, with tachyphylaxis (waning of the gastric-emptying delay) developing over subsequent weeks — though the appetite and weight-loss effects persist long after the gastric-emptying signal has attenuated. Marathe and colleagues’ 2013 Peptides review summarized the broader GLP-1 mechanism: native GLP-1 and pharmacologic GLP-1 receptor agonists delay gastric emptying in a dose-dependent fashion, and this deceleration extends to the small intestine and colon^[9].

Three additional factors stack on top of the direct motility effect:

• Lower food volume — tirzepatide’s appetite suppression is more profound than semaglutide’s in head-to-head trials (see tirzepatide vs. semaglutide head-to-head). Eating less means less fiber and less stool bulk. A 1,200-calorie day on tirzepatide without deliberate fiber planning often delivers under 10g of fiber, well below the 25–35g/day adult target^[10].
• Lower fluid intake — satiety on a GLP-1/GIP extends to thirst for many patients. The drink-with-meals prompt is weaker once you’re eating smaller portions.
• Concurrent antiemetics — if you’re using ondansetron (Zofran) for nausea during titration, that drug itself causes constipation, and the two effects stack. See our tirzepatide diarrhea management guide for the related GI-tolerance trade-off.

Practical relief protocol — fiber, fluids, magnesium, movement

The first-line relief protocol is conservative, well-supported, has no drug interactions, and is what most gastroenterologists recommend before any laxative.

Soluble fiber 25–35g/day

Anderson and colleagues’ 2009 Nutrition Reviews synthesis documented that dietary fiber consumption at or above the 25–35g/day adult target improves stool frequency, softness, and transit time, with soluble fiber (psyllium, oat beta-glucan, fruit pectin) showing the most consistent effect on constipation^[10]. On a 1,200–1,500 calorie tirzepatide day, hitting 25–35g of fiber requires deliberate planning — you cannot get there by accident on a typical Western reduced-calorie diet.

• Psyllium husk (Metamucil) — 1 tablespoon (~5g soluble fiber) in a full 8 oz glass of water, 1–3 times daily. The water is non-negotiable; psyllium without enough fluid can worsen constipation.
• Ground flaxseed — 1–2 tablespoons in yogurt, oatmeal, or a smoothie. ~3g fiber per tablespoon plus omega-3s.
• Chia seeds — 1–2 tablespoons, ideally hydrated for 10 minutes in liquid before eating. ~5g fiber per tablespoon.
• High-fiber whole foods — raspberries (8g per cup), pears with skin (5–6g each), avocado (10g each), lentils (15g per cup cooked), black beans (15g per cup), bran cereal (10g+ per serving).

Use our GLP-1 fiber calculator to plan a day that actually hits 25–35g; without planning, most tirzepatide patients land between 8–12g.

Hydration 2.5–3L/day

Fiber without enough fluid is a worse outcome than no fiber. Insoluble fiber needs water to soften stool; soluble fiber needs water to form the gel that lubricates transit. The standard recommendation for an adult on a tirzepatide titration is 2.5–3 liters of non-caffeinated fluid per day — this is also the volume that protects against the FDA-label acute kidney injury risk flagged in Mounjaro Section 5.3 and Zepbound Section 5^[1][2].

Magnesium citrate 200–400 mg at bedtime

Magnesium acts as an osmotic laxative in the colon — it pulls water into the bowel lumen, softening stool and accelerating transit. Mori and colleagues’ 2019 randomized double-blind placebo-controlled trial in the Journal of Neurogastroenterology and Motility demonstrated that oral magnesium oxide improved both stool frequency and consistency in chronic constipation patients vs. placebo over 28 days^[11]. Magnesium citrate is the better-absorbed form for daily use; magnesium oxide is the form studied in the Mori RCT.

• Starting dose — 200 mg magnesium citrate at bedtime. Titrate up to 400 mg if needed and tolerated.
• Side effects — loose stools or diarrhea if you overshoot. Drop the dose if this happens.
• Contraindications — chronic kidney disease (CKD stage 3+), since impaired kidneys cannot excrete excess magnesium and can develop hypermagnesemia. Confirm with your prescriber if you have any renal impairment.

Polyethylene glycol 3350 (MiraLAX)

PEG 3350 is the over-the-counter osmotic laxative most gastroenterologists recommend for adult constipation. It’s non-absorbed, has minimal side effects, and is safe for long-term use. Dose: 17g (one capful) in 8 oz of fluid once daily; can be increased to twice daily if needed.

Walking, gentle movement, and dose stability

Physical activity stimulates colonic motility. A 20–30 minute walk after a meal is one of the highest-leverage, zero-side-effect interventions for sluggish bowel transit. Morning walks are particularly effective because the gastrocolic reflex (the colon waking up after the first meal of the day) is the strongest intrinsic peristaltic signal you have.

Dose stability also matters. SURMOUNT-1, SURMOUNT-4, and the manufacturer’s prescribing recommendations support pausing dose escalation if GI tolerability is poor — staying at 5 mg or 7.5 mg for an extra month rather than escalating on schedule is a reasonable strategy that gives the gut time to adapt before the next step up^[3][4].

When to call your prescriber (red flags)

Both the Mounjaro and Zepbound FDA labels have been updated to acknowledge ileus — the functional shutdown of normal bowel peristalsis — as a postmarketing adverse reaction in the GLP-1/GIP class^[1][2]. Ileus can mimic ordinary tirzepatide constipation in its early presentation but progresses to a medical emergency. The distinguishing features:

• No bowel movement for 5+ days AND no passage of gas (obstipation is the cardinal sign — more concerning than just hard or infrequent stool).
• Progressive abdominal distension — visibly swollen abdomen that is firm to the touch.
• Severe abdominal pain, especially crampy or colicky pain in waves.
• Vomiting, particularly vomiting of bile (green or yellow) or feculent (foul-smelling, dark) material.
• Inability to keep down fluids — the combination of obstipation plus emesis can drive you into the dehydration zone that the FDA label warns can cause acute kidney injury.

Any combination of these symptoms warrants urgent evaluation — call your prescriber immediately, or go to an emergency department if you cannot reach them quickly. Bring your tirzepatide pen or the label so the treating team knows you’re on a dual GIP/GLP-1 agonist. Ileus and bowel obstruction can require nasogastric decompression, IV fluids, and in severe cases surgical intervention.

Pancreatitis (Mounjaro label Section 5.2, Zepbound Section 5.2) is another rare but serious consideration that overlaps with severe GI symptoms^[1][2]. Severe persistent abdominal pain that radiates to the back, with or without vomiting, warrants prompt evaluation regardless of whether constipation is the dominant symptom. The Zepbound label Section 5.7 also flags pulmonary aspiration risk during anesthesia in patients with retained gastric contents — another reason to disclose tirzepatide use ahead of any planned procedure.

How tirzepatide compares with semaglutide on constipation

Wilding and colleagues’ STEP-1 publication in the New England Journal of Medicine (2021) is the closest semaglutide comparator — same trial design (placebo-controlled, ~68–72 weeks, adults with obesity) and same primary GI adverse-event reporting methodology^[6]. STEP-1 reported constipation in approximately 24% of patients on semaglutide 2.4 mg (the Wegovy weight-loss dose) vs. 11% on placebo. Side-by-side with SURMOUNT-1’s ~11–12% constipation rate on tirzepatide 15 mg, the head-to-head picture is somewhat counterintuitive: even though tirzepatide’s dual GIP + GLP-1 mechanism produces more gastric-emptying delay on first dose, the trial-reported cumulative-constipation rates on weight-loss doses are lower for tirzepatide than for semaglutide 2.4 mg^[3][6].

Two caveats. First, the trials enrolled different patient populations and used different definitions of bothersome constipation, so direct rate-vs-rate comparisons need a grain of salt — the only fully head-to-head safety publication is SURMOUNT-5 (covered in our tirzepatide vs. semaglutide head-to-head article). Second, tirzepatide’s diarrhea rate is higher than semaglutide’s, suggesting some patients who would have been constipated on a GLP-1 mono-agonist are instead pushed into diarrhea-predominant GI tolerability by the GIP component — the net GI burden is comparable across the two drugs, just distributed differently along the constipation/diarrhea spectrum.

Related research and tools

• Ozempic constipation: causes, FDA-label rates & relief — the semaglutide sister article with side-by-side comparable rate tables
• Tirzepatide diarrhea: mechanism and management — the flip side of the same GI-motility coin
• Tirzepatide vs. semaglutide head-to-head — SURMOUNT-5, weight-loss magnitude, and full GI adverse-event comparison
• Mounjaro vs. Zepbound disambiguation — same drug, two brand labels, different indications
• GLP-1 side effect questions answered — the Q&A hub covering nausea, fatigue, hair loss, mood, and more
• GLP-1 side effect timeline tool — when each side effect peaks and resolves, by drug and week
• GLP-1 fiber calculator — plan a 25–35g/day fiber target on a reduced-calorie tirzepatide day

Important disclaimer. This article is educational and does not constitute medical advice. Constipation management decisions should always be made with your prescribing clinician, particularly if you have chronic kidney disease, heart failure, or are taking multiple other medications. If you have any of the red flag symptoms listed above (no stool for 5+ days plus abdominal pain or vomiting, progressive distension, inability to pass gas), seek care promptly.